ESTRO 2025 - Abstract Book

S2048

Clinical - Urology

ESTRO 2025

Conclusion: Preliminary results suggest that adding PART to WPRT and long-term ADT results in excellent oncological outcomes, particularly in the adjuvant setting, with acceptable toxicity levels. The PART Trial is ongoing, with final recruitment expected in 2025.

Keywords: Prostate Cancer, Lymph node, Para-aortic

References: 1. Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W, et al. Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Res Protoc. 2018;7(12):e11256.

3466

Digital Poster Outcomes following Stereotactic Radiotherapy to the Pelvis in the Oligometastatic setting having previously had Prostate Cancer Radiotherapy William S.G Hayhurst 1 , Susan Lalondrelle 2 , Asadullah A Khan 3 , Lei Wang 4 , Intan Hamid 5 , Babusha Kalra 5 , Vincent Khoo 6 , Nicholas van As 6 1 Urology, Royal Surrey County Hospital, Guildford, United Kingdom. 2 Gynaecology, Royal Marsden Hospital, London, United Kingdom. 3 Oncology, Royal Surrey County Hospital, London, United Kingdom. 4 Oncology, Royal Surrey County Hospital, Guildford, United Kingdom. 5 Oncology, Royal Marsden Hospital, London, United Kingdom. 6 Urology, Royal Marsden Hospital, London, United Kingdom Purpose/Objective: Pelvic recurrence following primary radiotherapy for prostate cancer produces a significant challenge, with uncertainty in the optimal management strategy. Stereotactic body radiation therapy (SBRT) offers an attractive salvage treatment option with its high conformity sparing normal tissue and higher doses taking advantage of the low alpha:beta ratio. Long term survival and toxicity outcomes of pelvic SBRT in the salvage setting are however limited 1,2 .